Fortress Biotech Inc. (FBIO)
NASDAQ: FBIO
· Real-Time Price · USD
3.71
0.87 (30.63%)
At close: Sep 05, 2025, 3:59 PM
3.95
6.47%
After-hours: Sep 05, 2025, 07:57 PM EDT
Fortress Biotech Revenue Breakdown
| Period Ending | Jun 30, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accutane Revenue | 3.4M | 7.87M | 4M | 5.72M | 5.82M | 15.52M | 5.58M | 4.65M | 4.14M | 4.12M | 5.2M | 4.91M |
| Accutane Revenue Growth | -56.86% | +96.92% | -30.13% | -1.72% | -62.51% | +178.19% | +20.03% | +12.14% | +0.58% | -20.75% | +5.97% | n/a |
| Amzeeq Revenue | 879K | 3.05M | 1.54M | 1.21M | 755K | 5.01M | 1.37M | 1.19M | 1.35M | 1.16M | 1.26M | 3.47M |
| Amzeeq Revenue Growth | -71.17% | +97.73% | +27.97% | +59.60% | -84.92% | +264.48% | +15.17% | -11.63% | +16.28% | -8.22% | -63.50% | n/a |
| Qbrexza Revenue | 6.95M | 13.26M | 7.58M | 6.84M | 5.02M | 21.32M | 8.08M | 4.09M | 6.96M | 6.26M | 6.11M | 7.38M |
| Qbrexza Revenue Growth | -47.60% | +74.88% | +10.93% | +36.26% | -76.46% | +163.84% | +97.34% | -41.20% | +11.14% | +2.52% | -17.15% | n/a |
| Zilxi Revenue | 256K | 1M | 558K | 369K | 273K | 1.65M | 572K | 314K | 422K | 554K | 555K | 741K |
| Zilxi Revenue Growth | -74.43% | +79.39% | +51.22% | +35.16% | -83.43% | +188.11% | +82.17% | -25.59% | -23.83% | -0.18% | -25.10% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 38.76M | 25.66M | 26.86M | 21.99M | 20.82M | 17.94M | 22.61M | 21.73M | 24.44M | 25.34M | 28.2M | 30.14M | 29.05M | 26.27M | 27.7M | 22.22M | 19.38M | 17.54M | 15.81M | 15.38M | 14.46M | 15.52M | 14.33M | 14.34M | 13.44M | 13.48M | -4.41M | 12.18M | 13.06M | 19.22M | 1.25M | 16.06M | 16.22M | 14.47M | 9.75M | 8.86M | 8.63M | 7.93M | 7.21M | 7.13M | 3.8M | 3.49M |
| Selling, General, and Administrative Revenue Growth | +51.02% | -4.47% | +22.15% | +5.62% | +16.06% | -20.66% | +4.04% | -11.07% | -3.56% | -10.14% | -6.44% | +3.76% | +10.57% | -5.16% | +24.65% | +14.65% | +10.49% | +10.97% | +2.76% | +6.41% | -6.85% | +8.30% | -0.06% | +6.67% | -0.26% | -405.55% | -136.20% | -6.68% | -32.07% | +1432.62% | -92.19% | -0.99% | +12.04% | +48.49% | +9.97% | +2.65% | +8.86% | +10.04% | +1.11% | +87.46% | +8.97% | n/a |
| Research and Development Revenue | 8.13M | 3.94M | 9.94M | 9.45M | 12.67M | 24.84M | 14.08M | 20.35M | 32.14M | 39.51M | 35.12M | 29.9M | 33.13M | 36.72M | 43.05M | 28.08M | 33.83M | 20.15M | 17.96M | 13.76M | 17.27M | 15.12M | 23.62M | 15.27M | 18.71M | 23.72M | 25.05M | 19.79M | 17.49M | 25.05M | 14.41M | 16.19M | 13.48M | 8.4M | 10.57M | 8.32M | 8.41M | 7.82M | 5.76M | 9.07M | 2.41M | 1.64M |
| Research and Development Revenue Growth | +106.35% | -60.38% | +5.23% | -25.45% | -48.99% | +76.46% | -30.82% | -36.69% | -18.64% | +12.49% | +17.45% | -9.75% | -9.78% | -14.71% | +53.33% | -17.01% | +67.88% | +12.20% | +30.58% | -20.36% | +14.26% | -36.00% | +54.68% | -18.38% | -21.13% | -5.30% | +26.60% | +13.15% | -30.20% | +73.88% | -11.00% | +20.08% | +60.44% | -20.53% | +27.16% | -1.08% | +7.52% | +35.84% | -36.56% | +276.32% | +46.83% | n/a |